Timing of cisplatin administration for chemoradiotherapy in transgenic mice bearing lens tumors

Kaku,Shoji; Ushioda,Norichika; Ishii,Hiroshi; Murakami,Takashi; Takahashi,Kentaro; Nakai,Yuichiro; Shimoya,Koichiro; Nakamura,Takafumi

doi:10.3892/or.2014.3202

Timing of cisplatin administration for chemoradiotherapy in transgenic mice bearing lens tumors

Authors:
- Shoji Kaku
- Norichika Ushioda
- Hiroshi Ishii
- Takashi Murakami
- Kentaro Takahashi
- Yuichiro Nakai
- Koichiro Shimoya
- Takafumi Nakamura
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Kawasaki Medical School, Okayama, Japan, Department of Obstetrics and Gynecology, Shiga University of Medical Science, Shiga, Japan
Published online on: May 20, 2014 https://doi.org/10.3892/or.2014.3202
Pages: 16-22
Copyright: © Kaku et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cisplatin-based concurrent chemoradiotherapy (CCRT) has become a standard treatment for cancer of the uterine cervix. However, there have been no investigations into the optimum timing for administration of anticancer drugs using animal models. The aim of the present study was to determine the appropriate timing for administration of the anticancer drug cisplatin in relation to delivery of radiation by assessing the antitumor activity and adverse effects of 3 different regimens in αT3 transgenic mice bearing lens epithelial tumors. CCRT showed the strongest antitumor activity. There was a significant difference between CCRT and administration of cisplatin before radiotherapy (neoadjuvant therapy) with regard to the apoptotic effect detected by TUNEL staining, but there was no significant difference between CCRT and administration of cisplatin after radiotherapy (adjuvant therapy). Assessment of adverse effects showed that there were no significant differences in the mortality rate, weight loss, anemia and leukopenia among the 3 regimens. In conclusion, these findings obtained in an animal model suggest that cisplatin should probably not be administered before irradiation, since the antitumor effect is significantly weaker than that of CCRT or administration after irradiation, while adverse effects are similar.

View Figures

View References

1	Kessis TD, Slebos RJ, Nelson WG, et al: Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. Proc Natl Acad Sci USA. 90:3988–3992. 1993. View Article : Google Scholar : PubMed/NCBI
2	Nees M, Geoghegan JM, Munson P, et al: Human papillomavirus type 16 E6 and E7 proteins inhibit differentiation-dependent expression of transforming growth factor-β2 in cervical keratinocytes. Cancer Res. 60:4289–4298. 2000.PubMed/NCBI
3	Parkin DM, Pisani P and Ferlay J: Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer. 54:594–606. 1993. View Article : Google Scholar : PubMed/NCBI
4	Runowicz CD, Wadler S, Rodriguez-Rodriguez L, et al: Concomitant cisplatin and radiotherapy in locally advanced cervical carcinoma. Gynecol Oncol. 34:395–401. 1989. View Article : Google Scholar : PubMed/NCBI
5	Alberts DS, Garcia D and Mason-Liddil N: Cisplatin in advanced cancer of the cervix: an update. Semin Oncol. 18:11–24. 1991.PubMed/NCBI
6	Malfetano J, Keys H, Kredentser D, Cunningham M, Kotlove D and Weiss L: Weekly cisplatin and radical radiation therapy for advanced, recurrent, and poor prognosis cervical carcinoma. Cancer. 71:3703–3706. 1993. View Article : Google Scholar : PubMed/NCBI
7	Whitney CW, Sause W, Bundy BN, et al: Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol. 17:1339–1348. 1999.
8	Sorbe B, Bohr L, Karlsson L and Bermark B: Combined external and intracavitary irradiation in treatment of advanced cervical carcinomas: Predictive factors for local tumor control and early recurrences. Int J Oncol. 36:371–378. 2010.
9	Morris M, Eifel PJ, Lu J, et al: Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 340:1137–1143. 1999. View Article : Google Scholar : PubMed/NCBI
10	Rose PG, Bundy BN, Watkins EB, et al: Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 340:1144–1153. 1999. View Article : Google Scholar : PubMed/NCBI
11	Eifel PJ, Winter K, Morris M, et al: Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol. 22:872–880. 2004. View Article : Google Scholar
12	Vokes EE and Weichselbaum RR: Concomitant chemoradiotherapy: rationale and clinical experience in patients with solid tumors. J Clin Oncol. 8:911–934. 1990.PubMed/NCBI
13	Tannock IF: Treatment of cancer with radiation and drugs. J Clin Oncol. 14:3156–3174. 1996.PubMed/NCBI
14	Randall LM, Monk BJ, Moon J, et al: Prospective evaluation of an in vitro radiation resistance assay in locally advanced cancer of the uterine cervix: a Southwest Oncology Group Study. Gynecol Oncol. 119:417–421. 2010. View Article : Google Scholar
15	Tanaka T, Bai T, Yukawa K and Umesaki N: Optimal combination chemotherapy and chemoradiotherapy with etoposide for advanced cervical squamous cancer cells in vitro. Oncol Rep. 15:939–947. 2006.PubMed/NCBI
16	Tanaka T, Yukawa K and Umesaki N: Radiation reduces carboplatin sensitivity and enhances nedaplatin sensitivity in cervical squamous cell carcinoma in vitro. Eur J Gynaecol Oncol. 28:352–355. 2007.
17	Egwuagu CE, Li W, Yu CR, et al: Interferon-γ induces regression of epithelial cell carcinoma: critical roles of IRF-1 and ICSBP transcription factors. Oncogene. 25:3670–3679. 2006.
18	Zheng HC, Nakamura T, Zheng Y, et al: SV40 T antigen disrupted the cell metabolism and the balance between proliferation and apoptosis in lens tumors of transgenic mice. J Cancer Res Clin Oncol. 135:1521–1532. 2009. View Article : Google Scholar : PubMed/NCBI
19	Fujii M, Ide A, Nakabayashi K, Joguchi A, Ogino H and Ayusawa D: The introduction of dominant-negative p53 mutants suppresses temperature shift-induced senescence in immortal human fibroblasts expressing a thermolabile SV40 large T antigen. J Biochem. 125:531–536. 1999. View Article : Google Scholar
20	Dueñas-González A, Cetina-Perez L, Lopez-Graniel C, et al: Pathologic response and toxicity assessment of chemoradiotherapy with cisplatin versus cisplatin plus gemcitabine in cervical cancer: a randomized Phase II study. Int J Radiat Oncol Biol Phys. 61:817–823. 2005.PubMed/NCBI
21	Verbraecken J, Van de Heyning P, De Backer W and Van Gaal L: Body surface area in normal-weight, overweight, and obese adults. A comparison study. Metabolism. 55:515–524. 2006. View Article : Google Scholar : PubMed/NCBI
22	Kumar L, Kaushal R, Nandy M, et al: Chemotherapy followed by radiotherapy versus radiotherapy alone in locally advanced cervical cancer: a randomized study. Gynecol Oncol. 54:307–315. 1994. View Article : Google Scholar
23	Tattersall MH, Lorvidhaya V, Vootiprux V, et al: Randomized trial of epirubicin and cisplatin chemotherapy followed by pelvic radiation in locally advanced cervical cancer. Cervical Cancer Study Group of the Asian Oceanian Clinical Oncology Association. J Clin Oncol. 13:444–451. 1995.
24	Sundfør K, Tropé CG, Högberg T, et al: Radiotherapy and neoadjuvant chemotherapy for cervical carcinoma. A randomized multicenter study of sequential cisplatin and 5-fluorouracil and radiotherapy in advanced cervical carcinoma stage 3B and 4A. Cancer. 77:2371–2378. 1996.
25	Shueng PW, Hsu WL, Jen YM, Wu CJ and Liu HS: Neoadjuvant chemotherapy followed by radiotherapy should not be a standard approach for locally advanced cervical cancer. Int J Radiat Oncol Biol Phys. 40:889–896. 1998. View Article : Google Scholar
26	Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trials. Eur J Cancer. 39:2470–2486. 2003. View Article : Google Scholar : PubMed/NCBI
27	Grégoire V, Hunter NR, Brock WA, Hittelman WN, Plunkett W and Milas L: Improvement in the therapeutic ratio of radiotherapy for a murine sarcoma by indomethacin plus fludarabine. Radiat Res. 146:548–553. 1996.
28	Milas L, Hunter N, Mason KA, Milross C and Peters LJ: Tumor reoxygenation as a mechanism of taxol-induced enhancement of tumor radioresponse. Acta Oncol. 34:409–412. 1995. View Article : Google Scholar : PubMed/NCBI
29	Milross CG, Mason KA, Hunter NR, et al: Enhanced radioresponse of paclitaxel-sensitive and-resistant tumours in vivo. Eur J Cancer. 33:1299–1308. 1997. View Article : Google Scholar : PubMed/NCBI
30	Suzuki M, Nakamatsu K, Kanamori S, Masunaga S and Nishimura Y: Additive effects of radiation and docetaxel on murine SCCVII tumors in vivo: special reference to changes in the cell cycle. Radiat Res. 159:799–804. 2003. View Article : Google Scholar : PubMed/NCBI
31	Singh RB, Chander S, Mohanti BK, et al: Neoadjuvant chemotherapy with weekly paclitaxel and carboplatin followed by chemoradiation in locally advanced cervical carcinoma: a pilot study. Gynecol Oncol. 129:124–128. 2013. View Article : Google Scholar : PubMed/NCBI
32	McCormack M, Kadalayil L, Hackshaw A, et al: A phase II study of weekly neoadjuvant chemotherapy followed by radical chemoradiation for locally advanced cervical cancer. Br J Cancer. 108:2464–2469. 2013. View Article : Google Scholar